Article
Oncology
Xiangdong Xu, Yang Liu, Yan Li, Huajian Chen, Yuxuan Zhang, Jie Liu, Shaokang Deng, Yaofeng Zheng, Xinlin Sun, Jihui Wang, Taoliang Chen, Min Huang, Yiquan Ke
Summary: MiR-375 expression is downregulated in gliomas, and it suppresses glioma proliferation, migration, and invasion by inhibiting the CTGF-EGFR signaling pathway. MiR-375-containing exosomes were found in human blood samples from glioma patients, with levels correlating with disease progression. Exosomal miR-375 secretion impacts the activity of the CTGF-EGFR pathway, and once secreted, exosomal miR-375 is not taken back up by glioma cells.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Dentistry, Oral Surgery & Medicine
Kaixin Wangzhou, Zishao Lu, Zhiying Lai, Wanren Fu, Cheng Liu, Yi Tan, Chunbo Hao
Summary: This study revealed that circ_0002141 is upregulated in OSCC tissues and cell lines, and its overexpression promotes the proliferation, migration, and invasion of OSCC cells while reducing apoptosis. It was also found that EGFR is a target of miR-1231 and circ_0002141 can sponge miR-1231 to upregulate EGFR expression in OSCC cells.
Article
Oncology
Jinpeng Hu, Guoqing Zhang, Yongfeng Wang, Kai Xu, Lian Chen, Gang Luo, Jinkun Xu, Hao Li, Dongmei Pei, Xiang Zhao, Zhengting Guo, Xinqiao Li, Shengliang Zong, Yang Jiang, Zhitao Jing
Summary: This study identifies a novel circular RNA, circGNB1, which is upregulated in glioma and closely associated with poor prognosis. Functional assays reveal that circGNB1 overexpression promotes the viability, proliferation, invasion, and neurosphere formation of glioma stem cells. Mechanistically, circGNB1 upregulates the expression of oncogene XPR1 by sponging miR-515-5p and miR-582-3p. XPR1, in turn, promotes the malignant phenotype of glioma stem cells through upregulating IL6 expression and activating JAK2/STAT3 signaling. Additionally, the RNA binding protein IGF2BP3 binds to and stabilizes circGNB1, thus enhancing its effects on glioma stem cells. This study uncovers the crucial role of circGNB1 in tumorigenesis and malignant progression of glioma, providing a promising cancer biomarker.
CANCER CELL INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Wen Peng, Shuang Shi, Jiacheng Zhong, Hanghua Liang, Jianbin Hou, Xiaosong Hu, Feng Wang, Jiayi Zhang, Shengjun Geng, Xiaochuan Sun, Dong Zhong, Hongjuan Cui
Summary: CBX3, also known as HP1 gamma, is upregulated in glioblastoma multiforme (GBM) and promotes cell proliferation, invasion, and tumorigenesis. It regulates the malignant progression of GBM through an EGFR-dependent mechanism. CBX3 directly suppresses the transcriptional levels of PARK2 and STUB1, reducing the ubiquitination of EGFR.
Article
Neurosciences
Faming Wang, Le Zhang, Yao Luo, Qingyun Zhang, Yueling Zhang, Yingying Shao, Liudi Yuan
Summary: This study identified and verified a novel lncRNA RP11-279C4.1 that was upregulated in glioma tissues and cell lines, and demonstrated its role in promoting tumor progression by modulating the miR-1273g-3p/CBX3 axis.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Chenlong Li, Xue Guan, Hanguang Jing, Xu Xiao, Hua Jin, Jinsheng Xiong, Siqi Ai, Yingjie Wang, Tianqi Su, Guiyin Sun, Tianjiao Fu, Yujie Wang, Shouli Guo, Peng Liang
Summary: The present study found that the circular RNA bifunctional apoptosis regulator (circBFAR) is highly expressed in glioblastoma multiforme (GBM) and is negatively correlated with overall survival in patients. Inhibition of circBFAR can suppress the proliferation and invasion of GBM. The study also identified that circBFAR regulates the expression of FoxM1 through interaction with miR-548b.
Article
Cell Biology
Xiaomin Cai, Wenjin Qiu, Mengshu Qian, Shuang Feng, Chenghao Peng, Jiale Zhang, Yi Wang, Yuhai Wang
Summary: CFI is overexpressed in glioma and is associated with poor outcomes, serving as a potential prognostic biomarker and driving malignant progression in glioma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Yongjun Hu, Ming Luo
Summary: This study found that miR-378c is lowly expressed in stomach adenocarcinoma (STAD) and is highly associated with poor prognosis and clinical characteristics. Overexpression of miR-378c can inhibit the malignant behaviors of STAD cells. Additionally, the study identified the target of miR-378c and its regulatory mechanism.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Deheng Li, Liangdong Li, Xin Chen, Wentao Yang, Yiqun Cao
Summary: A novel upregulated circRNA, circSERPINE2, was identified in glioblastoma, promoting tumor cell proliferation and progression by sponging miRNAs and enhancing the expression of the anti-apoptosis gene BCL2. This study reveals the biological function and mechanism of circSERPINE2 in glioblastoma progression, suggesting its potential as a therapeutic target.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Cell Biology
Yang Jiang, Junshuang Zhao, Yingliang Liu, Juntao Hu, Liang Gao, Hui Wang, Daming Cui
Summary: Glioma stem cells (GSCs) are a special kind of cells in GBM showing tumor initiation, self-renewal, and multi-lineage differentiation abilities. Finding novel circRNAs related to GSCs is of great significance for the study of glioma. Our study found that circKPNB1 is a novel oncogene in GBM and has great significance in the diagnosis and prognosis prediction of GBM.
CELL DEATH & DISEASE
(2022)
Article
Cell Biology
Qingdong Guo, Jun Guo, Wei Liu, Shijie Hu, Xuean Hu, Qianliang Wang, Xiaofan Jiang
Summary: This study identified the novel circRNA circ-EGFR as a regulator in glioma progression by modulating the levels of miR-183-5p and TUSC2. Circ-EGFR acted as a sponge for miR-183-5p and hindered glioma development. Targeting the miR-183-5p/TUSC2 axis, circ-EGFR showed potential as a therapeutic target for glioma progression.
CELLULAR AND MOLECULAR NEUROBIOLOGY
(2022)
Article
Oncology
Haiyang Wang, Haoran Li, Qianqian Jiang, Xuchen Dong, Suwen Li, Shan Cheng, Jia Shi, Liang Liu, Zhiyuan Qian, Jun Dong
Summary: Recent studies have shown that Glioma Stem-like Cells (GSCs) can induce malignant transformation of fibroblasts (t-FBs) in the tumor microenvironment through the HOTAIRM1/miR-133b-3p/TGF beta axis. This finding could potentially provide a new target for treating gliomas.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Zhikuan Yu, Ningwei Che, Yeting He, Bo Zhang
Summary: This study indicates that lncRNA MIR210HG is upregulated in glioma and inhibition of lncRNA MIR210HG can suppress glioma cell proliferation. LncRNA MIR210HG acts as a regulator of glioma cell proliferation by targeting miR-377-3p and inhibiting LMX1A.
Article
Cell Biology
Zhihuang Zhao, Gang Li, Yonggang Han, Yabin Li, Zhisheng Ji, Rui Guo, Xiaohong Yu
Summary: The circular RNA ZNF609 plays a critical role in regulating glioma by affecting cell growth, invasion, apoptosis, and glycolysis. ZNF609 modulates cell survival and glycolysis by targeting the miR-378b/SLC2A1 axis in glioma cells. ZNF609 and miR-378b may serve as potential therapeutic targets in treating glioma.
Review
Oncology
Colin Thorbinson, John-Paul Kilday
Summary: Brain tumors are the leading cause of childhood cancer deaths in developed countries, representing the most common solid tumor in this age group, accounting for approximately one-quarter of all pediatric cancers. Developments in neuro-imaging, neurosurgical techniques, adjuvant therapy, and supportive care have improved survival rates for certain tumors, allowing a focus on optimizing cure while minimizing long-term adverse effects. Recent advancements in the molecular characterization of common pediatric brain tumors have identified unique clinical and biological patient subgroups, but achieving a paradigm shift in translational therapy and subsequent survival for many tumors remains challenging, with recurrence presenting a significant clinical challenge. This review provides insight into key molecular developments and global cooperative trial results for the most common malignant pediatric brain tumors, highlighting potential future directions for management, including novel therapeutic options and unresolved critical challenges.